BioSig Technologies Inc. Expands into RWA Tokenization with Strategic Broker-Dealer Acquisition
In a significant strategic move, BioSig Technologies Inc., a leading medical technology company specializing in cardiac catheter ablation solutions, has announced its expansion into the realm of real-world asset (RWA) tokenization. This development marks a pivotal shift for the Nasdaq-listed company, traditionally known for its innovative contributions to health care equipment and supplies.
On July 14, 2025, BioSig Technologies partnered with Compliance Exchange Group (CXG) to acquire a FINRA/SEC-registered broker-dealer. This acquisition is set to bolster the company’s capabilities in RWA tokenization, positioning BioSig as a pioneer in issuing regulated, gold-backed RWA tokens. The move is part of a broader strategy to diversify its offerings beyond its core medical technology solutions.
The acquisition aligns with BioSig’s recent merger with Streamex Exchange Corporation, forming a unified entity poised to leverage its new capabilities in the financial technology space. This merger and subsequent acquisition are expected to enhance BioSig’s market presence, allowing it to tap into new revenue streams and investor bases.
The decision to venture into RWA tokenization comes at a time when the financial markets are witnessing a resurgence, underscored by Bitcoin’s recent all-time high. This broader market optimism may provide a conducive environment for BioSig’s new financial endeavors.
Despite the company’s current negative price-to-earnings ratio of -9.4 and a market cap of $819.6 million, the strategic pivot towards RWA tokenization could potentially unlock new growth avenues. Investors and market analysts are closely watching BioSig’s transition, anticipating how this diversification might impact its financial health and stock performance.
As BioSig Technologies embarks on this new chapter, it remains committed to its foundational mission of advancing health care technology while exploring innovative financial solutions. The company’s forward-looking approach reflects its adaptability and ambition to remain at the forefront of both medical and financial technology sectors.
For more information on BioSig Technologies and its latest developments, visit www.biosig.com .